Newcelx Ltd (NCEL) Stock Price, Quote & News

Company Profile

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 512 21 50

Fax: 41 44 512 21 51

Website: newcelx.com

Address:

Hohstrasse 1, Kloten, Switzerland

focafoca99 Jun. 5 at 8:42 PM

$NCEL conducts its annual shareholders' meeting on June 30, 2026.

0 · Reply

KuddyGage May. 27 at 5:27 PM

$NCEL did news come out Dumping

0 · Reply

DannyDff May. 27 at 2:28 PM

$NCEL anybody here?

1 · Reply

Travelling May. 27 at 2:02 PM

$VSEE I sold this in October at 2.29, also watching $RKTO, $NCEL, $SKLZ holding $CADL

0 · Reply

DannyDff May. 27 at 1:07 PM

$NCEL is this dead today

0 · Reply

XXX_TRADEZ May. 27 at 12:23 PM

$NCEL Low float under accumulation, watch for vol

0 · Reply

YoloAlfred May. 27 at 12:16 PM

$NCEL thats what im thinking out +$300

0 · Reply

TA_Kongen May. 27 at 12:16 PM

$NCEL Where is the pump? They need cash for their Phase 1 lol.

0 · Reply

DannyDff May. 27 at 12:12 PM

$NCEL PT?

0 · Reply

stocksbuytrade May. 27 at 12:10 PM

$NCEL 🧐

0 · Reply

NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA

ELDN

May 27, 2026, 7:55 AM EDT - 13 days ago

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

2026-05-11T22:55:46.000Z - 4 weeks ago

NewcelX files to sell 2.26M common shares for holders

Apr 30, 2026, 8:15 AM EDT - 5 weeks ago

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

2026-04-20T11:43:42.000Z - 7 weeks ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

ELDN

Apr 20, 2026, 7:37 AM EDT - 7 weeks ago

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Apr 1, 2026, 7:21 AM EDT - 2 months ago

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

2026-03-09T11:12:39.000Z - 3 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

ELDN

Mar 9, 2026, 7:00 AM EDT - 3 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

ELDN

Feb 12, 2026, 7:00 AM EST - 4 months ago

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

Jan 29, 2026, 7:00 AM EST - 4 months ago

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Jan 12, 2026, 7:00 AM EST - 5 months ago

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

Jan 5, 2026, 7:00 AM EST - 5 months ago

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

Dec 11, 2025, 7:00 AM EST - 6 months ago

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Nov 17, 2025, 7:00 AM EST - 7 months ago

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

Nov 6, 2025, 7:00 AM EST - 7 months ago

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

Nov 4, 2025, 7:00 AM EST - 7 months ago

NewcelX CEO Issues Letter to Shareholders

Nov 3, 2025, 8:25 AM EST - 7 months ago

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

NLSP

focafoca99 Jun. 5 at 8:42 PM

$NCEL conducts its annual shareholders' meeting on June 30, 2026.

0 · Reply

KuddyGage May. 27 at 5:27 PM

$NCEL did news come out Dumping

0 · Reply

DannyDff May. 27 at 2:28 PM

$NCEL anybody here?

1 · Reply

Travelling May. 27 at 2:02 PM

$VSEE I sold this in October at 2.29, also watching $RKTO, $NCEL, $SKLZ holding $CADL

0 · Reply

DannyDff May. 27 at 1:07 PM

$NCEL is this dead today

0 · Reply

XXX_TRADEZ May. 27 at 12:23 PM

$NCEL Low float under accumulation, watch for vol

0 · Reply

YoloAlfred May. 27 at 12:16 PM

$NCEL thats what im thinking out +$300

0 · Reply

TA_Kongen May. 27 at 12:16 PM

$NCEL Where is the pump? They need cash for their Phase 1 lol.

0 · Reply

DannyDff May. 27 at 12:12 PM

$NCEL PT?

0 · Reply

stocksbuytrade May. 27 at 12:10 PM

$NCEL 🧐

0 · Reply

JLCw May. 27 at 12:04 PM

$NCEL book thank you 🤝🔥

0 · Reply

YoloAlfred May. 27 at 12:02 PM

$NCEL added

0 · Reply

Stock_Catcher May. 27 at 11:55 AM

$NCEL NCEL NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

0 · Reply

MrTicker May. 27 at 11:35 AM

$NCEL EXCLUSIVE: NewcelX Submits Pre-IND Briefing Package To FDA for Type 1 Diabetes Therapy NCEL-101; Schedules Type B Pre-IND Meeting With FDA For Late June ( BENZINGA 6:32 AM ET 5/27/2026

0 · Reply

Stock_Catcher May. 27 at 11:32 AM

$NCEL Thin one

0 · Reply

yoni30 May. 6 at 6:37 PM

$NCEL How much longer will we wait for the start of the experiment?

0 · Reply

yoni30 May. 6 at 6:35 PM

$NCEL Without a supportive message, we will vomit everything And this is what happens

0 · Reply

islandpunk May. 4 at 8:29 PM

$NCEL 13D filed for 25% https://www.sec.gov/Archives/edgar/data/1783036/000121390026051611/xslSCHEDULE_13D_X02/primary_doc.xml

0 · Reply

topstockalerts May. 1 at 12:23 AM

$NCEL this is one of those setups you don’t want to ignore

0 · Reply

intrader Apr. 30 at 7:00 PM

$NCEL I'm all out.

0 · Reply

ScorpionScarlet Apr. 30 at 3:40 PM

$NCEL type I diabetes! Always a winner! 🥳🥳💕💰

0 · Reply

Market Cap	17.32M
Revenue (ttm)	0.00
Net Income (ttm)	-8.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.05

Volume	10,300
Avg Vol	62,958
Day's Range	N/A - N/A
Shares Out	5.35M
Stochastic %K	48%
Beta	0.94
Analysts	Strong Buy
Price Target	N/A